AANS Neurosurgeon | Volume 26, Number 4, 2017


Experimental Therapy Halts Treatment-resistant Brain Tumors

Researchers report lab breakthrough in human cells, mouse models for high grade gliomas

The protein encoded by the Olig2 gene is present in a vast majority of gliomas. Researchers have found that using a gene therapy can halt the growth of gliomas in both human cells and mouse models. Removing the Olig2 gene stops further tumor grown. Even further, removing or eliminating the Olig2-producing cells block any type of tumor formation. “We find that elimination of dividing Olif2-expressing cells block initiation and progression of glioma in animal models and further show that Olig2 is the molecular arbiter of genetic adaptability that makes high-grade gliomas aggressive and treatment resistant,” said Qing Richard Lu, PhD, lead investigator and scientific director of the Brain Tumor Center at Cincinnati Children’s. “By finding a way to inhibit Olig2 in tumor forming cells, we were able to change that tumor cells’ makeup and sensitize them to targeting molecular treatment. This suggests a proof for stratified therapy in distinct subtypes of malignant gliomas.” To read more, click here.


Winter Clinics for Cranial and Spinal Surgery
Feb. 25, 2018 - Mar. 1, 2018; Snowmass Village, Colo.

69th Southern Neurosurgical Society Annual Meeting
Feb. 28, 2018 - Mar. 3, 2018; San Juan, PR

Second International Brain Mapping Course
April 26-27, 2018; New Orleans

Comments are closed.